Anticipated ShortageTier 3 — Critical

ESTALIS 250/50 MCG

SANDOZ CANADA INCORPORATED

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is there a shortage of ESTALIS 250/50 MCG in Canada?

A shortage of ESTALIS 250/50 MCG 50MCG 250MCG is expected: the manufacturer reported it to Health Canada as an anticipated shortage (last updated October 29, 2026), but it has not started yet.

Why is ESTALIS 250/50 MCG not available?

The reason the manufacturer reported: Demand increase for the drug.

When will ESTALIS 250/50 MCG be available again?

The manufacturer's estimated resolution date is February 28, 2027. This is an estimate and can change; follow this page to get an email when the status changes.

Can I still get this?Check with your pharmacist

StatusAnticipated Shortage

Same-ingredient products on fileNone found

Expected resolution~4 months remaining (estimate)

Affected strength50MCG 250MCG

Report last updated2026-10-29

Checked by MedShort2026-11-12

What this means

Does this mean my pharmacy is already out of stock?

No — this shortage hasn't started yet. It's an early warning that supply may become tight, based on information from the manufacturer.

What should I do?

Health Canada classes this as a Tier 3 shortage, its highest-impact category. If you rely on this medication, ask your pharmacist or care team now, before the shortage starts, what the plan is if supply runs short.

Have you checked a pharmacy recently?

No community reports yet — be the first to share what you found.

Community reports are not verified by a pharmacy and may reflect a small sample size. This is not a guarantee of current stock.

DIN

02241837

Strength

50MCG 250MCG

Dosage Form

PATCH

Route

TRANSDERMAL

Active Ingredient

ESTRADIOL NORETHINDRONE ACETATE

Compare with another product →

Product Monograph

Product monograph is not available from Health Canada

View official Health Canada drug record ↗

Shortage Timeline

Approximate — based on the dates HPSC reports were last updated, not confirmed onset or resolution dates. Gaps between bars are periods with no shortage on file.

Active/anticipated Resolved

Shortage History

2026-10-29

Anticipated Shortage

Demand increase for the drug.

Other Products from SANDOZ CANADA INCORPORATED

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.

ACETYLCYSTEINE SOLUTION

200MG · DIN 02243098

ACLASTA

5MG · DIN 02269198

ALFENTANIL INJECTION USP

500MCG · DIN 02248181

AMIKACIN SULFATE INJECTION USP

250MG · DIN 02242971

AMIODARONE HYDROCHLORIDE FOR INJECTION

50MG · DIN 02242325

AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION

DIN 02495929